✨ Onyx Summary Phathom Pharmaceuticals announced dosing of the first patient in its Phase 2 pHalcon-EoE-201 trial evaluating VOQUEZNA (vonoprazan) tablets as a potential treatment for eosinophilic esophagitis in adults. The randomized, placebo-controlled study aims to assess VOQUEZNA’s efficacy and safety as a non-steroidal oral therapy for EoE, with topline
✨ Onyx Summary enGene Holdings was named to BioSpace’s 2026 Best Places to Work list, recognizing it among the top 50 U.S. life sciences employers for workplace culture and employee engagement. The honor reflects enGene’s continued growth and mission-driven focus as it advances its late-stage non-viral gene therapy,
✨ Onyx Summary Guardant Health launched a $250 million underwritten public offering of its common stock, with an additional $37.5 million option for underwriters, to be managed by Goldman Sachs, Jefferies, Leerink Partners, and Guggenheim Securities. Proceeds, alongside funds from a concurrent $300 million convertible notes offering, will be used
✨ Onyx Summary Guardant Health announced plans to offer $300 million in convertible senior notes due 2033 in a private placement to qualified institutional buyers, with an option for initial purchasers to buy an additional $45 million in notes. The company will use proceeds from this and a concurrent $250 million
✨ Onyx Summary Kyverna Therapeutics closed a $150 million non-dilutive loan facility with Oxford Finance, drawing an initial $25 million to support its late-stage autoimmune disease programs. The financing extends Kyverna’s cash runway into 2027 as it advances KYV-101 toward a Phase 3 trial in myasthenia gravis, prepares a BLA
✨ Onyx Summary Geron announced five presentations at the 2025 American Society of Hematology Annual Meeting, including new clinical and translational data on RYTELO (imetelstat) in lower-risk myelodysplastic syndromes and myelofibrosis. The presentations highlight long-term efficacy results from the Phase 3 IMerge trial and new analyses linking imetelstat’s biological activity
✨ Onyx Summary Phathom Pharmaceuticals announced its management team will participate in multiple investor conferences in November and December 2025, including events hosted by Guggenheim, Stifel, Jefferies, Craig-Hallum, and Evercore. Live and archived webcasts of select presentations will be available on the company’s investor relations website for 90 days following
✨ Onyx Summary Legend Biotech announced it will present eight abstracts on CARVYKTI® and new first-in-human data on Lucar-G39D at the 2025 ASH Annual Meeting, showcasing advances in CAR-T and allogeneic cell therapies. The presentations highlight CARVYKTI’s sustained efficacy and expanding real-world use in multiple myeloma, alongside early progress in
SAN DIEGO, Nov. 03, 2025 – Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, November 10, 2025, at 4:30 p.m. Eastern Time
✨ Onyx Summary Foghorn Therapeutics announced management participation in three upcoming investor events—the Guggenheim Healthcare Innovation, Stifel 2025 Healthcare, and Jefferies 2025 London Healthcare Conferences—featuring presentations by CEO Adrian Gottschalk. The company will use these forums to engage investors and highlight progress of its Gene Traffic Control® platform and
✨ Onyx Summary Belite Bio (NASDAQ: BLTE) said the UK MHRA will accept a Conditional Marketing Authorization application for Tinlarebant in Stargardt disease based on interim Phase 3 DRAGON results, with final topline data expected in Q4 2025 for subsequent full MAA submission. The pivotal DRAGON trial enrolled 104 adolescent patients
✨ Onyx Summary Perspective Therapeutics (NYSE American: CATX) announced its senior leadership will participate in the Truist Securities BioPharma Symposium on November 6, 2025, and the UBS Global Healthcare Conference on November 11, 2025, where it will host a fireside chat. The company continues to engage the investment community as it
✨ Onyx Summary Lexicon Pharmaceuticals (Nasdaq: LXRX) announced it will release its third-quarter 2025 financial results before market open on November 6, 2025, followed by a conference call and webcast at 8:30 a.m. ET to discuss results and provide a business update. THE WOODLANDS, TEXAS, OCT. 30, 2025 — Lexicon
✨ Onyx Summary Saama launched its Tables, Listings, and Figures (TLF) Analyzer, an AI-driven solution that automates interpretation and summarization of complex clinical data to accelerate clinical study report (CSR) authoring. Integrating multimodal GenAI capable of converting graphical outputs—such as Kaplan–Meier and forest plots—into context-rich text, the tool
✨ Onyx Summary Foghorn Therapeutics (Nasdaq: FHTX) announced advancements across its targeted protein degrader portfolio, including progress on its selective ARID1B, CBP, and EP300 degrader programs, with preclinical data showing promise in multiple solid and hematologic cancers and an IND filing for its CBP degrader planned for 2026. The updates underscore
✨ Onyx Summary Seer, Inc. (Nasdaq: SEER) announced its participation in upcoming investor events, including one-on-one meetings at the UBS Global Healthcare Conference on November 12 and a fireside chat at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20. Live and archived webcasts of the
